Evidence map›Paper›PMID 34597386›Full record

ArticleJournal of neuropathology and experimental neurology2021

Differences in Symptomatic Presentation and Cognitive Performance Among Participants With LATE-NC Compared to FTLD-TDP.

Merilee A Teylan, Charles Mock, Kathryn Gauthreaux, Jessica E Culhane, Gregory Jicha, Yen-Chi Chen, Kwun C G Chan, Walter A Kukull, Peter T Nelson, Yuriko Katsumata

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuropathology and experimental neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Identifying and Diagnosing TDP-43 Neurodegenerative Diseases in Psychiatry.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2024
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Merilee A TeylanFrom the National Alzheimer's Coordinating Center, Department of Epidemiology, University of Washington, Seattle, Washington, USA (MAT, CM, KG, JEC, Y-CC, KCGC, WAK); Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA (GJ, PTN, YK); Division of Neuropathology, Department of Pathology, University of Kentucky, Lexington, Kentucky, USA (PTN); Department of Biostatistics, University of Kentucky, Lexington, Kentucky, USA (YK).
Charles MockFrom the National Alzheimer's Coordinating Center, Department of Epidemiology, University of Washington, Seattle, Washington, USA (MAT, CM, KG, JEC, Y-CC, KCGC, WAK); Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA (GJ, PTN, YK); Division of Neuropathology, Department of Pathology, University of Kentucky, Lexington, Kentucky, USA (PTN); Department of Biostatistics, University of Kentucky, Lexington, Kentucky, USA (YK).
Kathryn GauthreauxFrom the National Alzheimer's Coordinating Center, Department of Epidemiology, University of Washington, Seattle, Washington, USA (MAT, CM, KG, JEC, Y-CC, KCGC, WAK); Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA (GJ, PTN, YK); Division of Neuropathology, Department of Pathology, University of Kentucky, Lexington, Kentucky, USA (PTN); Department of Biostatistics, University of Kentucky, Lexington, Kentucky, USA (YK).
Jessica E CulhaneFrom the National Alzheimer's Coordinating Center, Department of Epidemiology, University of Washington, Seattle, Washington, USA (MAT, CM, KG, JEC, Y-CC, KCGC, WAK); Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA (GJ, PTN, YK); Division of Neuropathology, Department of Pathology, University of Kentucky, Lexington, Kentucky, USA (PTN); Department of Biostatistics, University of Kentucky, Lexington, Kentucky, USA (YK).
Gregory JichaFrom the National Alzheimer's Coordinating Center, Department of Epidemiology, University of Washington, Seattle, Washington, USA (MAT, CM, KG, JEC, Y-CC, KCGC, WAK); Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA (GJ, PTN, YK); Division of Neuropathology, Department of Pathology, University of Kentucky, Lexington, Kentucky, USA (PTN); Department of Biostatistics, University of Kentucky, Lexington, Kentucky, USA (YK).
Yen-Chi ChenFrom the National Alzheimer's Coordinating Center, Department of Epidemiology, University of Washington, Seattle, Washington, USA (MAT, CM, KG, JEC, Y-CC, KCGC, WAK); Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA (GJ, PTN, YK); Division of Neuropathology, Department of Pathology, University of Kentucky, Lexington, Kentucky, USA (PTN); Department of Biostatistics, University of Kentucky, Lexington, Kentucky, USA (YK).ORCID 0000-0002-4485-306X
Kwun C G ChanFrom the National Alzheimer's Coordinating Center, Department of Epidemiology, University of Washington, Seattle, Washington, USA (MAT, CM, KG, JEC, Y-CC, KCGC, WAK); Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA (GJ, PTN, YK); Division of Neuropathology, Department of Pathology, University of Kentucky, Lexington, Kentucky, USA (PTN); Department of Biostatistics, University of Kentucky, Lexington, Kentucky, USA (YK).
Walter A KukullFrom the National Alzheimer's Coordinating Center, Department of Epidemiology, University of Washington, Seattle, Washington, USA (MAT, CM, KG, JEC, Y-CC, KCGC, WAK); Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA (GJ, PTN, YK); Division of Neuropathology, Department of Pathology, University of Kentucky, Lexington, Kentucky, USA (PTN); Department of Biostatistics, University of Kentucky, Lexington, Kentucky, USA (YK).
Peter T NelsonFrom the National Alzheimer's Coordinating Center, Department of Epidemiology, University of Washington, Seattle, Washington, USA (MAT, CM, KG, JEC, Y-CC, KCGC, WAK); Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA (GJ, PTN, YK); Division of Neuropathology, Department of Pathology, University of Kentucky, Lexington, Kentucky, USA (PTN); Department of Biostatistics, University of Kentucky, Lexington, Kentucky, USA (YK).
Yuriko KatsumataFrom the National Alzheimer's Coordinating Center, Department of Epidemiology, University of Washington, Seattle, Washington, USA (MAT, CM, KG, JEC, Y-CC, KCGC, WAK); Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA (GJ, PTN, YK); Division of Neuropathology, Department of Pathology, University of Kentucky, Lexington, Kentucky, USA (PTN); Department of Biostatistics, University of Kentucky, Lexington, Kentucky, USA (YK).
University of Washington · USUniversity of Kentucky · US

Funding

NATIONAL ALZHEIMERS COORDINATING CENTER (NACC)U01AG016976 · NIA · UNIVERSITY OF WASHINGTON · PI KUKULL, WALTER ANTHONY · 1999 to 2020
$72.8M
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI GRABOWSKI, THOMAS J. · 1985 to 2019
$57.2M
VIRUS-INDUCED BRAIN PATHOLOGYP50AG005131 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BREWER, JAMES B · 1985 to 2018
$55.4M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI FAGAN, ANNE · 1985 to 2019
$52.1M
SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI LEURGANS, SUE E. · 1991 to 2020
$49.1M
Satellite Diagnostic and Treatment Clinic CoreP50AG008702 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DE JAGER, PHILIP L · 1989 to 2019
$46.3M
National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
TREATMENT OF DEPRESSION IN ALZHEIMER'S DISEASEP50AG005133 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAMBOH, M. ILYAS · 1985 to 2019
$43.0M
THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 1985 to 2018
$42.1M
VASCULAR RISK AND COGNITIVE STATUS IN A LATINO POPULATIONP50AG005142 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BRASKIE, MEREDITH NICOLE · 1985 to 2019
$41.0M
VESICULAR LOCALIZATION AND FUNCTION OF PRESENILIN 1 FRAGMENTP50AG005138 · NIA · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI GROSSMAN, HILLEL · 1985 to 2019
$37.9M
'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI ALBERT, MARILYN S. · 1985 to 2019
$37.6M
NIA NIH HHS P30 AG008017NIA NIH HHS P30 AG008051NIA NIH HHS P30 AG010124NIA NIH HHS P30 AG010129NIA NIH HHS P30 AG010133NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG012300NIA NIH HHS P30 AG013846NIA NIH HHS P30 AG013854NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG028383NIA NIH HHS P30 AG035982NIA NIH HHS P30 AG049638NIA NIH HHS P30 AG053760NIA NIH HHS P50 AG005131NIA NIH HHS P50 AG005133NIA NIH HHS P50 AG005134NIA NIH HHS P50 AG005136NIA NIH HHS P50 AG005138NIA NIH HHS P50 AG005142NIA NIH HHS P50 AG005146NIA NIH HHS P50 AG005681NIA NIH HHS P50 AG008702NIA NIH HHS P50 AG016573NIA NIH HHS P50 AG016574NIA NIH HHS P50 AG023501NIA NIH HHS P50 AG025688NIA NIH HHS P50 AG033514NIA NIH HHS P50 AG047266NIA NIH HHS P50 AG047270NIA NIH HHS P50 AG047366NIA NIH HHS R01 AG054060NIA NIH HHS R01 AG057187NIA NIH HHS R01 AG061111NIA NIH HHS R21 AG061551NIA NIH HHS R56 AG057191NIA NIH HHS U01 AG016976NIA NIH HHS U24 AG072122NINDS NIH HHS RF1 NS118584
6 · The paper itself

Abstract

Transactive response DNA-binding protein 43 kDa (TDP-43) is aberrantly aggregated and phosphorylated in frontotemporal lobar degeneration of the TDP-43 type (FTLD-TDP), and in limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC). We examined data from the National Alzheimer's Coordinating Center to compare clinical features of autopsy-confirmed LATE-NC and FTLD-TDP. A total of 265 LATE-NC and 92 FTLD-TDP participants were included. Cognitive and behavioral symptoms were compared, stratified by level of impairment based on global clinical dementia rating (CDR) score. LATE-NC participants were older at death, more likely to carry APOE ε4, more likely to have Alzheimer disease neuropathology, and had lower (i.e. less severe) final CDR global scores than those with FTLD-TDP. Participants with FTLD-TDP were more likely to present with primary progressive aphasia, or behavior problems such as apathy, disinhibition, and personality changes. Among participants with final CDR score of 2-3, those with LATE-NC were more likely to have visuospatial impairment, delusions, and/or visual hallucinations. These differences were robust after sensitivity analyses excluding older (≥80 years at death), LATE-NC stage 3, or severe Alzheimer cases. Overall, FTLD-TDP was more globally severe, and affected younger participants, whereas psychoses were more common in LATE-NC.

Indexed as

CognitionAgedAged, 80 and overAge FactorsAlzheimer DiseaseAphasia, Primary ProgressiveApolipoprotein E4DelusionsFemaleFrontotemporal Lobar DegenerationHallucinationsHeterozygoteHumansLimbic SystemMaleMiddle AgedApolipoprotein E4FrontotemporalFTDNeuropsychiatricPlaquesTangles

Identifiers

PMID34597386
PMCPMC8921612
OpenAlexW3202710185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.